Discovery of Covalent MKK4/7 Dual Inhibitor
Author:
Funder
Dana-Farber Cancer Institute
Publisher
Elsevier BV
Subject
Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Biology,Molecular Medicine,Biochemistry
Reference29 articles.
1. Multiplierz v2.0: a Python-based ecosystem for shared access and analysis of native mass spectrometry data;Alexander;Proteomics,2017
2. JNK signalling in cancer: in need of new, smarter therapeutic targets;Bubici;Br. J. Pharmacol.,2014
3. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases;Cargnello;Microbiol. Mol. Biol. Rev.,2011
4. Drug combination studies and their synergy quantification using the Chou-Talalay method;Chou;Cancer Res.,2010
5. Synthesis and biological evaluation of 3-arylindazoles as selective MEK4 inhibitors;Deibler;ChemMedChem,2019
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. MKK4 inhibitor: the hope for liver failure prevention and potential small liver graft transplantation;Chinese Journal of Natural Medicines;2024-06
2. Molecular Bidents with Two Electrophilic Warheads as a New Pharmacological Modality;ACS Central Science;2024-02-26
3. Covalent drugs based on small molecules and peptides for disease theranostics;Biomaterials Science;2024
4. Repurposing of FDA approved kinase inhibitor bosutinib for mitigation of radiation induced damage via inhibition of JNK pathway;Toxicology and Applied Pharmacology;2024-01
5. MKK4 Inhibitors—Recent Development Status and Therapeutic Potential;International Journal of Molecular Sciences;2023-04-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3